Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred ...

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 20).

A 26-year-old woman was referred to the pulmonary hypertension clinic with a 6-month history of exertional dyspnea and hoarseness. Vocal-fold paralysis was seen on laryngoscopy (shown in a video).

To the Editor: The results of the C-POST trial, reported by Rischin and colleagues (August 21/28 issue), 1 highlight improvements in disease-free survival with adjuvant cemiplimab. As the authors ...

A federal appeals court ruling in United States v. Safehouse may open the door to a new legal defense for harm-reduction interventions in a hostile political climate.

Joshua Barocas is an associate professor of medicine at the University of Colorado Anschutz Medical Campus. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.

The U.S. antitrust paradigm can’t fully counteract the risks posed by health care corporatization. Regulators need robust procompetitive strategies to recenter patients and health as measures of ...

More than 470,000 patients with kidney failure receive hemodialysis in the United States alone, with worldwide estimates approaching 3 million patients. Mortality from kidney failure remains ...

Somatic mutations in EGFR (epidermal growth factor receptor) account for approximately one third of lung cancer cases worldwide.1 A point mutation in exon 21 (L858R) or a short deletion in exon 19 ...

To the Editor: The CONFIDENCE trial, conducted by Agarwal et al. (Aug. 7 issue), 1 showed that combination therapy with finerenone and empagliflozin led to a significantly greater reduction in the ...